SEC ownership of Satellos Bioscience Inc.

Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001421642.

Comparable stake leader

Qiming U.S. Healthcare Fund III, L.P.

Disclosed value leader

Qiming U.S. Healthcare Fund III, L.P.

Comparable rows

33/33

Latest evidence

31 Mar 2026

Ownership snapshot CIK-linked ownership evidence from parsed SEC filings. 2 signals
Latest 13D/G holder
Qiming U.S. Healthcare Fund III, L.P.
Latest parsed ownership date
31 Mar 2026
Issuer Names, identifiers, and filing context for this profile. 2 identity fields
Issuer CIK
0001421642
Issuer location
Toronto, Ontario, Canada

Ownership snapshot

Top shareholders of Satellos Bioscience Inc. (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
Qiming U.S. Healthcare Fu...
Disclosed value leader
Qiming U.S. Healthcare Fu...
Comparable rows
33/33
Latest evidence
31 Mar 2026
13D/G 13F Lead comparable stake: 8.3% 13D/G row: Qiming U.S. Healthcare Fund III, L.P. Showing 1-8 of 33 holder rows.

Quick read

Qiming U.S. Healthcare Fund III, L.P. leads the comparable SEC ownership view at 8.3%.

33 of 33 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens Qiming U.S. Healthcare Fund III, L.P.'s linked filing trail.
Comparable ownership Top 5
Qiming U.S. Healthcare Fund III, ... 8.3%
Brian Matthew Bloom 7.4%
FRANKLIN RESOURCES INC 6.1%
Siren, L.L.C. 5.8%
Vivo Capital, LLC 5.3%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-8 of 33 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
Qiming U.S. Healthcare Fund III, L.P.
13D/G
8.3%
$9,713,658
1,725,247 shares
$0 31 Mar 2026
Brian Matthew Bloom
13D/G
7.4%
$6,381,048
1,133,401 shares
$0 06 Feb 2026
FRANKLIN RESOURCES INC
13F
Company
13F
6.1%
$5,305,467
938,666 shares
31 Mar 2026
Siren, L.L.C.
13F
Individual
13F
5.8%
$5,022,377
892,074 shares
31 Mar 2026
Vivo Capital, LLC
13F
Company
13F
5.3%
$4,580,940
813,666 shares
31 Mar 2026
Point72 Asset Management, L.P.
13F
Company
13F
4.5%
$3,889,080
690,778 shares
31 Mar 2026
Woodline Partners LP
13F
Company
13F
3.2%
$2,817,432
500,432 shares
31 Mar 2026
SPHERA FUNDS MANAGEMENT LTD.
13F
Company
13F
3.2%
$2,754,235
489,207 shares
31 Mar 2026
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Forms 3/4/5 flow

Insider trading overview

Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 06 Jun 2025.

Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value Sell value
Shares: 0 Shares: 0
Window (months) Buy shares Sell shares Buy value Sell value Net value
0-3 0 0 $0 $0 $0
3-6 0 0 $0 $0 $0
6-9 0 0 $0 $0 $0
9-12 0 0 $0 $0 $0

Recent insider transactions for Satellos Bioscience Inc.

Showing up to 300 recent insider transactions from the last 12 months.

Insider Symbol Class Transaction % SEC-reported value SEC-reported price Shares Shares owned Date Ownership
No insider transactions were found in the last 12 months for this issuer.
* marks a reported price that did not pass the local price check.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .